论文部分内容阅读
目的:探讨部分性脾动脉栓塞术(PSE)治疗原发性肝癌合并脾功能亢进的临床疗效及安全性。方法:选择2008年5月至2013年4月我科收治的160例原发性肝癌合并有脾功亢进患者为研究对象,患者在行肝动脉化疗栓塞术(TACE)的同时进行PSE,PSE栓塞面积在30%~60%之间,观察治疗后3天、7天、1个月、3个月、6个月患者白细胞(WBC)计数和血小板(PLT)计数的动态变化情况。结果:以外周血白细胞计数达到4.0~13×109/L、血小板达计数到50×109/L为治疗有效,160例患者术后3个月时外周血白细胞治疗有效为151例(94.38%),血小板治疗有效为155例(96.88%),术后6个月时白细胞治疗有效136例(85%),血小板治疗有效125例(78.13%)。所有患者术后6个月均未发生严重并发症。结论:PSE联合TACE治疗原发性肝癌合并有脾功亢进患者具有良好的疗效,且安全性较高。
Objective: To investigate the clinical efficacy and safety of partial splenic arterial embolization (PSE) in the treatment of primary hepatocellular carcinoma complicated with hypersplenism. Methods: From May 2008 to April 2013, 160 patients with primary liver cancer complicated with hypersplenism admitted to our department were enrolled in this study. Patients undergoing transcatheter arterial chemoembolization (TACE) with PSE and PSE embolism The area of 30% -60%. The changes of white blood cell (WBC) counts and platelet (PLT) counts were observed at 3 days, 7 days, 1 month, 3 months and 6 months after treatment. Results: Peripheral blood leukocyte count was 4.0 ~ 13 × 109 / L and platelet count reached 50 × 109 / L. The effective rate of peripheral white blood cells in 160 patients was 151 cases (94.38%) at 3 months after operation. 155 cases (96.88%) were effective for platelet therapy, 136 cases (85%) were effective leukocyte therapy and 125 cases (78.13%) were effective platelet therapy at 6 months after operation. No serious complications occurred in all patients after 6 months. Conclusion: PSE combined with TACE in the treatment of primary hepatocellular carcinoma patients with hypersplenism has good curative effect and high safety.